# Reducing Severe Breathlessness with Dronabinol in Severe COPD Patients > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dronabinol-copd-breathlessness-trial-protocol-review/ > **Published:** 2026-04-27T02:20:05-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:09:58-04:00 > **Clinical Summary:** Explore the dronabinol COPD breathlessness trial protocol reviewing synthetic THC's potential to ease severe breathlessness in COPD patients. --- CED Clinical Relevance  #91High Clinical Relevance Evidence Brief | CED ClinicRandomized crossover trial will evaluate dronabinol for severe breathlessness in COPD patients with persistent symptoms despite optimal treatment. CopdBreathlessnessDronabinolThcRct Table of Contents - [Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark](#Reducing_severe_breathlessness_with_dronabinol_in_the_group_of_patients_with_severe_and_very_severe_chronic_obstructive_pulmonary_disease_BONG_a_randomised_double-blinded_placebo-controlled_crossover_study_in_an_outpatient_clinic_in_Denmark) - [FAQ](#FAQ)[What is dronabinol and how might it help COPD patients with severe breathlessness?](#What_is_dronabinol_and_how_might_it_help_COPD_patients_with_severe_breathlessness) - [Who are the ideal candidates for this dronabinol treatment approach?](#Who_are_the_ideal_candidates_for_this_dronabinol_treatment_approach) - [What does the treatment protocol involve for patients in this study?](#What_does_the_treatment_protocol_involve_for_patients_in_this_study) - [How is the effectiveness of dronabinol measured in treating breathlessness?](#How_is_the_effectiveness_of_dronabinol_measured_in_treating_breathlessness) - [What are the potential clinical implications if dronabinol proves effective for COPD breathlessness?](#What_are_the_potential_clinical_implications_if_dronabinol_proves_effective_for_COPD_breathlessness) - [Related](#Related) ## Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark Randomized crossover trial will evaluate dronabinol for severe breathlessness in COPD patients with persistent symptoms despite optimal treatment. What This Study Teaches Us This protocol describes a methodologically sound crossover design to evaluate cannabinoids for COPD-related breathlessness, addressing a significant unmet clinical need. The crossover design allows each patient to serve as their own control, potentially reducing variability in this heterogeneous patient population. Why This Matters Severe COPD patients often experience persistent breathlessness despite optimal bronchodilator and [anti-inflammatory therapy](https://cedclinic.com/over-the-counter-cannabidiol-products-uk-quality-analysis/), leaving clinicians with limited options. Cannabis-based medicines represent a potential novel approach for this distressing symptom that significantly impacts quality of life. Study Snapshot Study Type Randomized Controlled Crossover Trial Protocol Population 30 adults with severe/very severe COPD and persistent breathlessness despite optimal treatment Intervention Dronabinol (synthetic THC) for 4 weeks Comparator Placebo for 4 weeks with 2-week washout between treatments Primary Outcome Breathing discomfort measured on 0-10 Numerical Rating Scale Key Finding Study protocol published – no results reported Journal BMJ Open Year 2024 Clinical Bottom Line This well-designed study protocol will provide needed evidence on whether synthetic THC can reduce breathlessness in severe COPD patients who remain symptomatic on standard care. The crossover design and validated outcome measures strengthen the potential clinical relevance of future results. What This Paper Does Not Show This is a protocol paper with no actual efficacy or safety data reported. The study has not yet been completed, so no conclusions about dronabinol’s effectiveness for COPD breathlessness can be drawn from this publication. Where This Paper Deserves Skepticism The small sample size of 30 patients may limit statistical power and generalizability. Blinding may be challenging given THC’s psychoactive effects, and the 4-week treatment periods may not capture long-term efficacy or tolerance development. Dr. Caplan's Take I’m encouraged to see rigorous study design being applied to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) in COPD, as breathlessness is indeed a devastating symptom with limited treatment options. However, we need to see the actual results before making any clinical recommendations about dronabinol for this indication. What a Careful Reader Should Take Away This protocol represents thoughtful research design for evaluating cannabinoids in severe COPD, but provides no efficacy data. Clinicians should await study completion before considering any practice changes regarding [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) for COPD breathlessness. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Reducing%20severe%20breathlessness%20with%20dronabinol%20in%20the%20group%20of%20patients%20with%20severe%20and%20very%20severe%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fdronabinol-copd-breathlessness-trial-protocol-review%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fdronabinol-copd-breathlessness-trial-protocol-review%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Reducing%20severe%20breathlessness%20with%20dronabinol%20in%20the%20group%20of%20patients%20with%20severe%20and%20very%20severe%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fdronabinol-copd-breathlessness-trial-protocol-review%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) ## FAQ #### What is dronabinol and how might it help COPD patients with severe breathlessness? Dronabinol is a synthetic form of THC (tetrahydrocannabinol), the active compound in cannabis. This study investigates whether dronabinol can reduce breathing discomfort in patients with severe COPD who continue to experience persistent breathlessness despite receiving optimal standard treatment. #### Who are the ideal candidates for this dronabinol treatment approach? The study targets patients aged 18 years and older with severe to very severe COPD who experience persistent breathlessness despite optimal medical management. Patients with ongoing infections, substance abuse history, or significant comorbidities are excluded from consideration. #### What does the treatment protocol involve for patients in this study? Patients receive either dronabinol or placebo for 4 weeks, followed by a 2-week washout period, then cross over to the [alternative treatment](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) for another 4 weeks. This crossover design allows each patient to serve as their own control, improving the reliability of results. #### How is the effectiveness of dronabinol measured in treating breathlessness? The primary outcome measures breathing discomfort using a 0-10 Numerical Rating Scale to assess the unpleasantness of breathlessness. Secondary outcomes include lung function tests, quality of life questionnaires, functional assessments, and plasma THC concentrations to evaluate comprehensive treatment effects. #### What are the potential clinical implications if dronabinol proves effective for COPD breathlessness? If successful, this could provide a new therapeutic option for the most severely affected COPD patients who have exhausted standard treatments. Given the study’s high clinical relevance rating, positive results could lead to expanded research and potential integration into clinical practice guidelines for managing refractory breathlessness in severe COPD. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Reducing Severe Breathlessness with Dronabinol in Severe COPD Patients](https://cedclinic.com/dronabinol-copd-breathlessness-trial/) Detailed insights into the randomized trial evaluating dronabinol for breathlessness in severe COPD patients. [Read the full study](https://cedclinic.com/dronabinol-copd-breathlessness-trial/) [Cannabinoid Clinical Trials: Mental Health Evidence Review](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/) Review of [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) assessing cannabinoids' effects on mental health conditions. [Explore mental health trials](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/) [Cannabinoids for Nerve Pain: What the Best Clinical Evidence Says About Sleep and Pain Relief](https://cedclinic.com/cannabinoid-therapy-neuropathic-pain-sleep-relief/) Clinical evidence summary on cannabinoids' role in neuropathic pain and sleep improvement. [Learn about cannabinoids and pain](https://cedclinic.com/cannabinoid-therapy-neuropathic-pain-sleep-relief/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).